VAR2 Pharmaceuticals founder and member of the Board of Directors, Prof. Poul Sorensen, will give a talk with the title “Probing the surface proteome for immunotherapy targets in high-risk pediatric cancers” on Saturady April 14th at the AACR meeting in Chicago, IL. The presentation will highlight s......
New significant data about chondroitin sulphate – the target for the VAR2 protein – in prostate cancer, will be presented on April 18th, at this year's AACR meeting in Chicago, IL. The work is presented in a poster entitled “Expression and regulation of chondroitin sulfate in prostate cancer” and is......
Today the Innovation Fund Denmark (innovationsFonden) granted 1 million DKK over 3 years to VAR2 Pharmaceuticals and Copenhagen University to fund an Industry PhD student in the project “Cancer immunotherapy based on a malaria protein”. We are very happy for the grant and look forward to work with t......
VAR2 Pharmaceuticals will take part in the 23rd annual BIO-Europe partnering conference, 6-8 November 2017, in Berlin. With a full meeting schedule we look forward to have many fruitful discussions with potential partners in the pharma and biotech industry. See you there!